Orkambi Approved to Treat Younger Cystic Fibrosis Patients

Vertex is also introducing Orkambi oral granules in 2 dosage strengths.
Vertex is also introducing Orkambi oral granules in 2 dosage strengths.

The Food and Drug Administration (FDA) has approved Orkambi (lumacaftor/ivacaftor; Vertex) for use in children 2 to 5 years old with cystic fibrosis (CF) who have 2 copies of the F508del-CFTR mutation. The treatment was previously only approved for patients ≥6 years.

The approval was based on data from a 24-week, open-label, Phase 3 study in patients aged 2 to 5 years (N=60) which showed a similar safety profile to that in patients ≥6 years. In addition, improvements in sweat chloride were observed at week 24 in this age group (mean absolute change from baseline was -31.7mmol/L; 95% CI: -35.7, -27.6). The efficacy and safety of Orkambi has not been established in children younger than 2 years old. 

Related Articles

“Research suggests Orkambi could impact CF outcomes in patients as young as 2 years old," said Dr John McNamara, Medical Director of the cystic fibrosis program at Children's Minnesota hospital and lead study researcher. "This approval is a significant development that enables physicians to begin treating the underlying cause of the disease in this population earlier than ever before.”

Related Articles

Vertex is also introducing Orkambi oral granules in 2 dosage strengths (lumacaftor 100mg/ivacaftor 125mg and lumacaftor 150mg/ivacaftor 188mg) for weight-based dosing. The granules can be mixed with soft food or liquid and should be ingested within 1 hour of mixing. The oral granules are expected to be available in 2 to 4 weeks in cartons containing 56 unit-dose packets.

For more information visit Vrtx.com.